• Search

Discovery Stems From Here

Human iPS cells, human primary cells, reagents, biochemicals, cytokines & antibodies...

Welcome to Axol Bioscience


Our mission is to create the best human cell biology research tools, to advance medical research and drug discovery.

Axol Bioscience are human cell culture specialists, providing primary cells and iPSC derived cells with a wide range of functionally and physiologically, disease relevant backgrounds, together with optimised media and growth supplements. all of which are suitable for assays in basic life science research, drug discovery and toxicology assessment. Our cells are provided cryopreserved, in a vial, as assay-ready live plated cells or as part of a custom service, where we use our extensive expertise to reprogram to iPS cells and differentiate into multiple cell types according to your specifications.

Latest News

  • Using hiPSC-Derived Renal Proximal Tubular Cells in vitro assays to advance disease research and drug development

    The rising numbers of kidney patients and a shortage of transplantable organs is a global health issue with high economic costs. Previous disease research and drug development has traditionally used animal models, but these fail to recapitulate human renal cellular function and so limit our ability to elucidate disease mechanisms and therapeutic targets.

  • Induced Pluripotent Stem Cells: recapitulating disease to facilitate drug discovery

    Download our free white paper ‘Induced Pluripotent Stem Cells: recapitulating disease to facilitate drug discovery‘

  • Using human iPSC-derived cortical neurons for the early prediction of neurotoxicity

    All pharmaceutical development programs carry a certain amount of risk. However, when it comes to developing drugs that target the central nervous system, the odds of success narrow significantly.

  • Society of Toxicology (SOT) 2018

    We are attending the SOT Annual Meeting 2018 in Texas, from 11-15 March 2018. We will be available throughout the conference at booth 760 as well as in our workshop, March 12. Join us!

  • The rise of hiPSC-Derived Motor Neurons as a physiologically relevant model for drug discovery

    Amyotrophic Lateral Sclerosis (ALS), a Motor Neuron Disease (MND) subtype, is a debilitating neurodegenerative disorder affecting the upper and lower motor neurons (UMNs/LMNs), brain stem and spinal cord. This leads to progressive muscular weakness and atrophy, paralysis, and eventually death, usually within three to five years after the onset of symptoms. Decades of failed drug development mean that MND/ALS is still incurable; only two FDA-approved drugs exist (riluzole, and more recently, edaravone), but these only slow down disease progression.